Cisen Pharmaceutical Co., Ltd. (603367.SS)
CNY 13.42
(-0.37%)
CNY 13.42
(-0.37%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 451.24 Million | 258.34 Million | 233.59 Million | 431 Million | 181.26 Million | 406.67 Million |
| Net Income | 525.42 Million | 352.38 Million | 333.9 Million | 437.36 Million | 514.79 Million | 503.05 Million |
| Depreciation & Amortization | 233.88 Million | 230.25 Million | 219.49 Million | 159.98 Million | 164.48 Million | 177.58 Million |
| Deferred income taxes | 8.11 Million | 2.52 Million | -19.07 Million | 4.1 Million | 5.69 Million | -9.41 Million |
| Stock-based compensation | 19.29 Million | 10.31 Million | 11.69 Million | 798.63 Thousand | - | - |
| Change in working capital | -354.13 Million | -324.04 Million | -260.97 Million | -108.86 Million | -439.54 Million | -260.69 Million |
| Other non-cash items | 8.71 Million | -16.89 Million | -51.43 Million | -62.38 Million | -58.47 Million | -13.26 Million |
| Investing Cash Flow | -378.12 Million | -273.07 Million | 327.48 Million | -47.02 Million | -144.99 Million | -1.37 Billion |
| Investments in PPE | -17.7 Million | -35.19 Million | -51.01 Million | -202.26 Million | -103.37 Million | -40.35 Million |
| Acquisitions | 1.17 Million | - | 491.66 Thousand | 2.42 Million | 80 Thousand | 1.43 Million |
| Investment purchases | -2.8 Billion | -800 Thousand | -4.21 Billion | -6.29 Billion | -6.29 Billion | -4.16 Million |
| Sales/Maturities of investments | 46.76 Million | 37.12 Million | 122.62 Million | 238.05 Million | 89.63 Million | 46.19 Million |
| Other Investing Activities | -407.94 Million | -274.21 Million | 4.46 Billion | 6.21 Billion | 6.16 Billion | -1.33 Billion |
| Financing Cash Flow | -133.8 Million | 108.19 Million | -318.43 Million | -83.95 Million | -19.04 Million | -69.06 Million |
| Debt repayment | -1.5 Million | -230 Million | -338 Million | -100.1 Million | -100 Million | -2.74 Million |
| Dividends payments | -151.67 Million | -135.85 Million | -115.93 Million | -120.18 Million | -118.77 Million | -71.81 Million |
| Common Stock Repurchased | - | - | - | -89.82 Million | - | - |
| Common Stock Issuance | - | - | - | 42.73 Million | - | - |
| Other Financing Activities | 27.42 Million | 477.73 Million | 140.29 Million | 343.21 Million | 200 Million | 2.74 Million |
| Accounts receivables | -336.44 Million | -542.34 Million | -113.29 Million | -221.34 Million | -350.77 Million | -222.8 Million |
| Accounts payables | 118.5 Million | 197.67 Million | -113.8 Million | 106.46 Million | -122.58 Million | 96.96 Million |
| Inventory | -144.3 Million | 18.09 Million | -14.8 Million | 1.91 Million | 28.12 Million | -125.45 Million |
| Other working capital | -4.92 Million | 2.52 Million | -19.07 Million | 4.1 Million | 5.69 Million | -135.24 Million |
| Cash at beginning of period | 995.68 Million | 901.57 Million | 659.14 Million | 361.66 Million | 344.09 Million | 1.38 Billion |
| Cash at end of period | 935.64 Million | 995.68 Million | 901.57 Million | 659.14 Million | 361.66 Million | 344.09 Million |
| Capital Expenditure | -17.7 Million | -35.19 Million | -51.01 Million | -202.26 Million | -103.37 Million | -40.35 Million |
| Effect of forex changes on cash | 646.75 Thousand | 649.15 Thousand | -217.48 Thousand | -2.54 Million | 343.87 Thousand | 122.36 Thousand |
| Net cash flow / Change in cash | -60.03 Million | 94.11 Million | 242.42 Million | 297.47 Million | 17.56 Million | -1.03 Billion |
| Free Cash Flow | 433.53 Million | 223.15 Million | 182.57 Million | 228.74 Million | 77.89 Million | 366.32 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 127.8 Million | 107.45 Million | 162.86 Million | 525.42 Million | 130.89 Million | 126.29 Million |
| Depreciation & Amortization | - | 59.02 Million | 59.02 Million | 233.88 Million | 233.88 Million | -89.81 Million |
| Deferred income taxes | - | - | - | 8.11 Million | - | 167.94 Million |
| Stock-based compensation | - | 4.82 Million | - | 19.29 Million | 19.29 Million | -6.22 Million |
| Change in working capital | - | -143.9 Million | - | -354.13 Million | -485.67 Million | -81.74 Million |
| Other non-cash items | 59.73 Million | -94.74 Million | 82.16 Million | 8.71 Million | 200.96 Million | 41.27 Million |
| Investing Cash Flow | -245.93 Million | 15.92 Million | -221.43 Million | -378.12 Million | -47.92 Million | -52.36 Million |
| Investments in PPE | -10.98 Million | -32.27 Million | -28.32 Million | -17.7 Million | 5.76 Million | -5.54 Million |
| Acquisitions | 6462.00 | - | 48 Thousand | 1.17 Million | 735.47 Thousand | 178.13 Thousand |
| Investment purchases | 1.53 Billion | -1.53 Billion | - | -2.8 Billion | -2.79 Billion | -7.63 Million |
| Sales/Maturities of investments | 18.35 Million | 1.37 Billion | 10.84 Million | 46.76 Million | 8.5 Million | 12.08 Million |
| Other Investing Activities | -253.29 Million | 204 Million | -204 Million | -407.94 Million | -72.91 Million | -51.44 Million |
| Financing Cash Flow | -16.4 Million | -200.87 Million | -70.01 Million | -133.8 Million | -20.65 Million | 40.41 Million |
| Debt repayment | -20 Million | -94.07 Million | -30 Million | -1.5 Million | -1 Million | -40 Million |
| Dividends payments | -1.71 Million | -197.4 Million | -1.34 Million | -151.67 Million | -1.93 Million | -3.06 Million |
| Common Stock Repurchased | - | - | - | - | -5 Million | 511.97 Thousand |
| Common Stock Issuance | - | - | - | - | - | -511.97 Thousand |
| Other Financing Activities | 5.3 Million | 90.69 Million | -98.66 Million | 27.42 Million | -17.99 Million | 83.47 Million |
| Accounts receivables | - | -31.69 Million | - | -336.44 Million | -336.44 Million | -289.19 Million |
| Accounts payables | - | - | - | 118.5 Million | - | -10.71 Million |
| Inventory | - | -89.18 Million | - | -144.3 Million | -144.3 Million | 207.44 Million |
| Other working capital | - | -23.01 Million | - | -4.92 Million | -4.92 Million | 10.71 Million |
| Cash at beginning of period | 658.04 Million | 937.03 Million | 983.38 Million | 995.68 Million | 926.36 Million | 780.57 Million |
| Cash at end of period | 564.42 Million | 705.85 Million | 937.03 Million | 935.64 Million | 935.64 Million | 926.36 Million |
| Capital Expenditure | -10.98 Million | -32.27 Million | -28.32 Million | -17.7 Million | 5.76 Million | -5.54 Million |
| Effect of forex changes on cash | -464.05 Thousand | 26.97 Thousand | 70.09 Thousand | 646.75 Thousand | 50.54 Thousand | 1858.23 |
| Net cash flow / Change in cash | -93.62 Million | -231.18 Million | -46.34 Million | -60.03 Million | 9.28 Million | 145.78 Million |
| Free Cash Flow | 176.54 Million | -78.59 Million | 216.7 Million | 433.53 Million | 85.84 Million | 152.18 Million |
JMT
NCI
AJB
SYNE3
000983
300845